Tags

Type your tag names separated by a space and hit enter

CoMFA and HQSAR studies on 6,7-dimethoxy-4-pyrrolidylquinazoline derivatives as phosphodiesterase10A inhibitors.
Bioorg Med Chem. 2008 Apr 01; 16(7):3675-86.BM

Abstract

Phosphodiesterase10A (PDE10A) is an important enzyme with diverse biological actions in intracellular signaling systems, making it an emerging target for diseases such as schizophrenia, Huntington's disease, and diabetes mellitus. The objective of the current 3D QSAR study is to uncover some of the structural parameters which govern PDE10A inhibitory activity over PDE3A/B. Thus, comparative molecular field analysis (CoMFA) and hologram quantitative structure-activity relationship (HQSAR) studies were carried out on recently reported 6,7-dimethoxy-4-pyrrolidylquinazoline derivatives as PDE10A inhibitors. The best CoMFA model using atom-fit alignment approach with the bound conformation of compound 21 as the template yielded the steric parameter as a major contributor (nearly 70%) to the observed variations in biological activity. The best CoMFA model produced statistically significant results, with the cross-validated (r(cv)(2)) and conventional correlation (r(ncv)(2)) coefficients being 0.557 and 0.991, respectively, for the 21 training set compounds. Validation of the model by external set of six compounds yielded a high (0.919) predictive value. The CoMFA models of PDE10A and PDE3A/B activity were compared in order to address the selectivity issue of these inhibitors. The best HQSAR model for PDE10A was obtained with an r(cv)(2) of 0.704 and r(ncv)(2) of 0.902 using atoms, bonds, connections, chirality, donor, and acceptor as fragment distinction and default fragment size of 4-7 with three components for the 21 compounds. The HQSAR model predicted the external test-set of compounds well since a good agreement between the experimental and predicted values was verified. Taken together, the present QSAR models were found to accurately predict the PDE10A inhibitory activity of the test-set compounds and to yield reliable clues for further optimization of the quinazoline derivatives in the dataset.

Authors+Show Affiliations

Department of Pharmaceutical Sciences, College of Pharmacy and Allied Health Professions, St. John's University, 8000 Utopia Parkway, Jamaica, NY 11439, USA.No affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

18299198

Citation

Kulkarni, Shridhar S., et al. "CoMFA and HQSAR Studies On 6,7-dimethoxy-4-pyrrolidylquinazoline Derivatives as phosphodiesterase10A Inhibitors." Bioorganic & Medicinal Chemistry, vol. 16, no. 7, 2008, pp. 3675-86.
Kulkarni SS, Patel MR, Talele TT. CoMFA and HQSAR studies on 6,7-dimethoxy-4-pyrrolidylquinazoline derivatives as phosphodiesterase10A inhibitors. Bioorg Med Chem. 2008;16(7):3675-86.
Kulkarni, S. S., Patel, M. R., & Talele, T. T. (2008). CoMFA and HQSAR studies on 6,7-dimethoxy-4-pyrrolidylquinazoline derivatives as phosphodiesterase10A inhibitors. Bioorganic & Medicinal Chemistry, 16(7), 3675-86. https://doi.org/10.1016/j.bmc.2008.02.013
Kulkarni SS, Patel MR, Talele TT. CoMFA and HQSAR Studies On 6,7-dimethoxy-4-pyrrolidylquinazoline Derivatives as phosphodiesterase10A Inhibitors. Bioorg Med Chem. 2008 Apr 1;16(7):3675-86. PubMed PMID: 18299198.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - CoMFA and HQSAR studies on 6,7-dimethoxy-4-pyrrolidylquinazoline derivatives as phosphodiesterase10A inhibitors. AU - Kulkarni,Shridhar S, AU - Patel,Maulik R, AU - Talele,Tanaji T, Y1 - 2008/02/08/ PY - 2007/11/18/received PY - 2008/01/26/revised PY - 2008/02/04/accepted PY - 2008/2/27/pubmed PY - 2008/5/16/medline PY - 2008/2/27/entrez SP - 3675 EP - 86 JF - Bioorganic & medicinal chemistry JO - Bioorg Med Chem VL - 16 IS - 7 N2 - Phosphodiesterase10A (PDE10A) is an important enzyme with diverse biological actions in intracellular signaling systems, making it an emerging target for diseases such as schizophrenia, Huntington's disease, and diabetes mellitus. The objective of the current 3D QSAR study is to uncover some of the structural parameters which govern PDE10A inhibitory activity over PDE3A/B. Thus, comparative molecular field analysis (CoMFA) and hologram quantitative structure-activity relationship (HQSAR) studies were carried out on recently reported 6,7-dimethoxy-4-pyrrolidylquinazoline derivatives as PDE10A inhibitors. The best CoMFA model using atom-fit alignment approach with the bound conformation of compound 21 as the template yielded the steric parameter as a major contributor (nearly 70%) to the observed variations in biological activity. The best CoMFA model produced statistically significant results, with the cross-validated (r(cv)(2)) and conventional correlation (r(ncv)(2)) coefficients being 0.557 and 0.991, respectively, for the 21 training set compounds. Validation of the model by external set of six compounds yielded a high (0.919) predictive value. The CoMFA models of PDE10A and PDE3A/B activity were compared in order to address the selectivity issue of these inhibitors. The best HQSAR model for PDE10A was obtained with an r(cv)(2) of 0.704 and r(ncv)(2) of 0.902 using atoms, bonds, connections, chirality, donor, and acceptor as fragment distinction and default fragment size of 4-7 with three components for the 21 compounds. The HQSAR model predicted the external test-set of compounds well since a good agreement between the experimental and predicted values was verified. Taken together, the present QSAR models were found to accurately predict the PDE10A inhibitory activity of the test-set compounds and to yield reliable clues for further optimization of the quinazoline derivatives in the dataset. SN - 1464-3391 UR - https://www.unboundmedicine.com/medline/citation/18299198/CoMFA_and_HQSAR_studies_on_67_dimethoxy_4_pyrrolidylquinazoline_derivatives_as_phosphodiesterase10A_inhibitors_ DB - PRIME DP - Unbound Medicine ER -